News
2021.12.17
(In order from the left) Lee Won-taek, Head of the Marketing Division, Byeon Ju-yeon, Head of the Pharmacological Mechanism Team, and Noh Yeong-su, Head of the Clinical Science Team honored at the 2nd Proud Hanmi Member Awards
The 2nd Proud Hanmi Member Awards was held at the Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul on the morning of Dember 17.
Three people were selected by Song Young-sook, Chairwoman of the Hanmi Pharmaceutical Group: Lee Won-taek, Head of the Marketing Division, Byeon Ju-yeon, Head of the Pharmacological Mechanism Team, and Noh Yeong-su, Head of the Clinical Science Team.
The award winners were presented with a plaque created in consultation with Chairwoman Song by artist Ko Myung-geun, a world-renowned artist in the fields of photography, sculpture, and architectural art, and a gold bar purchased by the Chairwoman.
The Proud Hanmi Member Awards was launched last year with Chairwoman Song wishing to select and reward employees who have demonstrated exceptional performance worthy of recognition based on creativity, innovation, and an enterprising spirit, which are considered important virtues by the Hanmi Pharmaceutical Group. The award recipients are limited to the employees, not the executives, in reflection of the Chairwoman’s will to discover and encourage front-line workers who created results behind the scenes.
One of this year’s winners, Division Head Lee Won-taek (Circulatory System Team, Marketing Division) was recognized for greatly enhancing the brand value of the Amosartan family, one of Hanmi Pharm’s main product lines. The sales of the Amosartan family in 2021 reached KRW 129 billion, an 8.1% YOY increase, and it is projected to surpass the 1-trillion-won sales mark in about a decade since its initial release in 2009.
Team Manager Byeon Ju-yeon (Pharmacological Mechanism Team), on the other hand, was honored with the award for securing the basis for setting the direction of pharmacological mechanism R&D for new synthetic drug projects (FLT3, EZH1/2, PIKfyve inhibitors, etc.) and helping the company gain a competitive advantage by discovering the SYK inhibition mechanism of HM43239, an FLT3 inhibitor.
Team Manager Noh Yeong-su (Clinical Science Team) contributed to the licensing of the FLT3 inhibitor, HM43239, by Aptose and spearheaded the efforts to obtain evidence for a global clinical trial for the purpose of expanding the scope of indications for the innovative anticancer drug, Belvarafenib, currently being developed by Genentech, a subsidiary of Roche.
Song Young-sook, Chairwoman of the Hanmi Pharmaceutical Group, said, “We decided to present this award at the end of every year to encourage employees who fulfilled their responsibilities throughout the year and were at the forefront of the company’s fearless journey to become a global group and a pharmaceutical powerhouse. [...] I hope that the significance and value of this award are conveyed to the members of the Hanmi Pharmaceutical Group and become firmly incorporated into the organizational culture.”
Source: Uihak Sinmun (Medical Newspaper)